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BACKGROUND AND PURPOSE
Proteinase-activated receptors (PARs) and toll-like receptors (TLRs) are involved in innate immune responses. The aim of this
study was to evaluate the possible cross-talk between PAR2 and TLR4 in vessels in physiological condition and how it varies
following stimulation of TLR4 by using in vivo and ex vivo models.
EXPERIMENTAL APPROACH
Thoracic aortas were harvested from both naïve and endotoxaemic rats for in vitro studies. Arterial blood pressure was
monitored in anaesthetized rats in vivo. LPS was used as a TLR4 agonist while PAR2 activating peptide (AP) was used as a PAR2
agonist. Aortas harvested from TLR4–/– mice were also used to characterize the PAR2 response.
KEY RESULTS
PAR2, but not TLR4, expression was enhanced in aortas of endotoxaemic rats. PAR2AP-induced vasorelaxation was increased in
aortic rings of LPS-treated rats. TLR4 inhibitors, curcumine and resveratrol, reduced PAR2AP-induced vasorelaxation and
PAR2AP-induced hypotension in both naïve and endotoxaemic rats. Finally, in aortic rings from TLR4–/– mice, the expression of
PAR2 was reduced and the PAR2AP-induced vasodilatation impaired compared with those from wild-type mice and both
resveratrol and curcumine were ineffective.
CONCLUSIONS AND IMPLICATIONS
Cross-talk between PAR2 and TLR4 contributes to vascular homeostasis.
Abbreviations
Chl, chlorisondamine; CRC, curcumine; MABP, mean arterial blood pressure; PAR2AP, protease activated receptor-2
activating peptide; PE, phenylephrine; RSV, resveratrol; TLR4, toll like receptor-4
Introduction
Proteinase-activated receptor 2 (PAR2) is a member of the
seven-transmembrane GPCR superfamily activated by proteo-
lytic cleavage (Macfarlane et al., 2001; Hollenberg and
Compton, 2002). All PARs share a unique mechanism of
activation where the serine proteases cleave at specific sites
within the extracellular N-terminus to unmask a tethered
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ligand domain that interacts with the receptor in the extra-
cellular loop II initiating signalling. This process is irrevers-
ible because once cleaved, PARs can no longer be used by the
cell, so they are degraded and signalling is terminated (Cot-
trell et al., 2003). Thus far, four PAR receptors have been
described: PAR1, PAR2, PAR3 and PAR4 (Hollenberg, 1999).
While the ligand for PAR1, PAR3 and PAR4 has been identified
as thrombin, PAR2 can be activated by trypsin (Nystedt et al.,
1994), tryptase (Molino et al., 1997) and factor Xa (Fox et al.,
1997), but not thrombin (Cicala, 2002). PAR2 can be activated
by a specific synthetic peptide [PAR2 activating peptide (AP) ],
which, by mimicking the specific tethered ligand sequence
SLIGRL, can activate the receptor without causing proteolysis
(Dery et al., 1998). In the last decade, we and others have
demonstrated that PAR2 is expressed in vascular tissues and
exposure to LPS results in it being up-regulated both in vitro
and in vivo, suggesting a possible role for PAR2 in endo-
toxaemia (Nystedt et al., 1996; Cicala et al., 1999; Morello
et al., 2005). The notion that PAR2 is overexpressed in
inflammatory-based diseases is supported by the literature;
however, it has not been well established whether this recep-
tor has a protective or detrimental role (Bucci et al., 2005).
Recently, a new emerging family of receptors has been
identified as a front line subsystem against invasive microor-
ganisms for both innate and adaptive immunity namely toll-
like receptors (TLR) (Iwasaki and Medzhitov, 2004). To date,
12 TLRs have been identified in both vertebrates and inver-
tebrates (Hoffmann and Reichhart, 2002; Roach et al., 2005),
and all of them are involved in triggering defensive antimi-
crobial immune responses (Akira and Hemmi, 2003; Akira
et al., 2006; Zhang and Schluesener, 2006). TLRs recognize
specific motifs found in microorganisms, but not in eukaryo-
tes, designed as pathogen-associated molecular patterns
(PAMPs) (Aderem and Ulevitch, 2000; Janeway and Medzhi-
tov, 2002). Once activated by PAMPs, TLRs initiate a signal
transduction cascade that leads to NF-kB activation with the
production of pro-inflammatory cytokines, such as TNF-a,
IL-1 and IL-6 (Barton and Medzhitov, 2004; Mitchell et al.,
2007). In particular, TLR4 signal transduction has been rec-
ognized as a key pathway for the lipid A moiety of LPS, from
gram-negative bacteria, to induce activation of various cells
stimulating widespread inflammation and activating coagu-
lation cascades (Lolis and Bucala, 2003; O’Neill and Bowie,
2007; Nakamura et al., 2008).
Recent studies have demonstrated that PARs, together
with TLRs and nucleotide-binding oligomerization domain
(NOD) receptors, are a part of the innate immune response.
Indeed, a complex interplay between the different receptors
of these three families is required for appropriate innate
immune responses to different types of bacteria; this
bacterial–host communication leads to the activation of
several signal transduction pathways with consequent pro-
duction of cytokines, antimicrobial peptides and apoptosis
(Chung et al., 2010). In this context, it has been demon-
strated that PAR2 activation participates in the patho-
genesis of periodontitis caused by Porphiromonas gingivalis
(Holzhausen et al., 2006), colitis caused by Citrobacter roden-
tium (Hansen et al., 2005), and in infections sustained by
Serratia marcescens (Kida et al., 2007) and Pseudomonas aerugi-
nosa (Kida et al., 2008). Moreover, it has been shown that
in transiently PAR2–transfected HEK293T cells, a synergistic
action between PAR2 and TLR4 takes place, suggesting coop-
eration between these two receptors in NF-kB–mediated
inflammatory responses (Rallabhandi et al., 2008). These
findings clearly suggest interplay between PAR2 and TLR4 in
infection-based inflammatory diseases, where PAR2 and TLR4
activation is enhanced, and their cooperation is valuable.
However, the cross-talk between PAR22 and TLR4 in normal
physiological environments has been less well investigated.
Hence, the aim of this study was to use in vivo and ex vivo
models to evaluate any possible cross-talk between PAR2 and
TLR4 in vascular tissues in physiological conditions and how
it varies following stimulation of TLR4.
Methods
Animals
All studies involving animals are reported in accordance with
the ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). Male
C57BL/10ScN mice and male Wistar rats (total number of rats
used = 50) were purchased from Harlan, Udine, Italy. Male
C57BL/10Cr (TLR4–/–) mice were a generous gift from Prof. S.
Cuzzocrea, University of Messina, Italy. All mice used for the
experiments (total number used = 60) were 6–8 weeks of age.
Animals were kept at a temperature of 23  2°C, humidity
range of 40 to 70% and 12h light/dark cycles. Food and water
were available ad libitum.
TLR4–/– mice were homozygous for a 74-kb genomic dele-
tion encompassing Tlr4 that resulted in the absence of both
its mRNA and protein and made them refractory to the bio-
logical activity of LPS (Poltorak et al., 1998; 2000). All animal
procedures were performed according to the Declaration of
Helsinki of the European Community guidelines for the use
of experimental animals and authorized by Centro Servizi
Veterinari Università degli Studi di Napoli ‘Federico II’.
Reagents
PAR2AP (SLIGKV-NH2) was synthesized by standard solid-
phase 9-fluorenylmethoxycarbonyl chemistry with an auto-
mated peptide synthesizer (model 432A, Applied Biosystems,
Carlsbad, CA, USA). Peptide was purified by reverse-phase
HPLC, and its identity was confirmed by MS, as described
previously. Urethane, heparin, resveratrol (RSV), curcumine
(CRC), ACh, phenylephrine (PE), DMSO, SOD and LPS from
Escherichia coli 0.127:B8 were purchased from Sigma Chemi-
cal Co. (Milan, Italy). Chlorisondamine (Chl) was purchased
from Tocris Cookson (Avon, England).
Blood pressure measurement
Male Wistar rats (Harlan) weighing 250–300 g were anaesthe-
tized with urethane (solution 15% wtvol-1; 1.5 g·kg-1 i.p.).
depth anaesthesia was assessed by checking both abdominal
and pedal withdrawal reflex throughout the duration of the
experiment. Once anaesthetized, rats were pretreated with
the irreversible ganglion-blocking agent, Chl (2.5 mg·kg-1
i.p.) in order to eliminate any influence of autonomic
nervous system activation on changes in mean arterial blood
pressure (MABP) induced by PAR2AP (Cicala et al., 2001). The
right jugular vein and the left carotid artery were cannulated
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for drug administration and blood pressure measurement,
respectively. The left carotid artery was connected to a pres-
sure transducer (Ugo Basile, Comerio, Italy) and changes
in arterial blood pressure were recorded continuously with
a computerized system (Biopac System TCI 102; Ugo Basile).
CRC (100 mg·kg-1) or RSV (30 mg·kg-1) were administered by
oral gavage 1 h before an i.v. injection of PAR2AP. After
surgery, arterial blood pressure was allowed to stabilize for
about 30 min. Once the blood pressure was stable, PAR2AP
(0.3 mg·kg-1) or vehicle (saline) was administered i.v. every
20 min for three consecutive times, and blood pressure was
monitored for a total time of 60 min. The change in MABP, as
previously described, (Cicala et al., 1999) was characterized
by a rapid fall lasting 1 min. There was no tolerance to the
hypotensive effect of PAR2AP (data not shown). Groups of six
rats for each treatment were used. Blood pressure values were
expressed as MABP calculated as area under the curve
obtained following PAR2AP administration. The MABP values
were monitored every 10 s up to 1 min.
Ex vivo studies
Male Wistar rats (Harlan) weighing 250–300 g (n = 4 for each
group of treatment) were anaesthetized with enflurane, then
LPS (13.5 ¥ 106 U·kg-1) or an equal volume of saline, was
injected i.v. through the caudal vein. The dose of LPS was
chosen from a previous study (Cicala et al., 1999). Four and
8 h after LPS or saline administration, the animals were killed
and thoracic aortas was rapidly harvested, dissected and
cleaned of adherent connective and fat tissue. Rings of
2–3-mm length were cut and placed in organ baths (2.5 mL)
filled with oxygenated (95% O2 -5% CO2) Krebs solution
maintained at 37°C. The rings were connected to an isometric
transducer (type 7006, Ugo Basile) and changes in tension
were recorded continuously with a computerized system
(Data Capsule 17400, Ugo Basile). The composition of the
Krebs solution was as follow (mM): NaCl 118, KCl 4.7, MgCl2
1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, and glucose 10.1. The
rings were initially stretched until a resting tension of 0.5 g
was reached and allowed to equilibrate for at least 30 min,
during which tension was adjusted, when necessary, to 0.5 g
and bathing solution was periodically changed. In each
experiment, rings were first challenged with PE (1 mM) until
the responses were reproducible. To verify endothelium
integrity, a cumulative concentration–response curve to ACh
(10 nM–30 mM) was performed on PE-precontracted rings.
The rings were then washed and contracted with PE
(1 mM) and, once a plateau was reached, a cumulative
concentration–response curve to PAR2AP (10 nM–30 mM) was
performed. A preliminary study on the optimal incubation
time and concentration of the drug treatments was carried
out (data not shown). CRC (10 mM; 15 min), RSV (10 mM;
15 min), SOD (300 U·mL-1; 15 min) or vehicle (DMSO) were
added in the organ baths; then the rings were contracted with
PE (1 mM) and a cumulative concentration–response curve to
PAR2AP was performed.
In another set of experiments, a cumulative
concentration–response curve to PAR2AP, in the presence
of CRC (10 mM; 15 min), RSV (10 mM 15 min) or vehicle
(DMSO) was carried out on aortic rings harvested from both
TLR4–/– and C57BL/10ScN mice. Data are expressed as %
vasodilatation induced by the stimulus, when applied after a
stable contraction had been obtained to 1 mM PE.
Quantification by real-time quantitative
reverse transcriptase PCR (RT-PCR)
The presence of PAR2 mRNA was determined by quantitative
PCR. Briefly, total RNA from tissues of naive and LPS-treated
rats, and naïve and LPS TLR4–/– and respective wild-type strain
C57BL/10ScN was extracted by using TRIzol reagent (Invitro-
gen, Milan, Italy). Subsequently, to eliminate genomic DNA
contamination, 1 mg of the above RNA was treated with RQ1
RNase-free DNase I (Promega Corporation, Madison, WI,
USA) and reverse transcription was performed using M-MLV
Reverse Transcriptase (Invitrogen) according to the manufac-
turer’s recommendations. Real-time RT-PCR was carried out
with cDNAs by using Sybr Green PCR Master Mix (Applied
Biosystems, Monza, Italy) and 7500 Real Time PCR System
(Applied Biosystems, Foster City, CA, USA). All cDNA samples
were run in triplicate in 25 mL reactions. Primers used were
specifically designed using Primer Express Software 2.0
(Applied Biosystems) and validated for their specificity:
FW:5’-CCGGGACGCAACAACAGTA-3’ RV:5’-TTCCCAGTGA
TTGGAGGCTG-3product length = 71. GAPDH was used as
internal control.
Samples were incubated at 50°C for 2 min and at 95°C for
10 min followed by 40 cycles at 95°C for 15 s and 60°C for
1 min. Differences in cDNA input were corrected by normal-
izing signals obtained with primers specific for GAPDH. To
exclude non-specific amplification and/or the formation of
primer dimers, control reactions were performed in the
absence of target cDNA. Gene expression levels were calcu-
lated using the 2-DCT method (Livak and Schmittgen, 2001)
and are presented as ratio between mean fold change of target
gene and GAPDH  SEM.
Western blotting
Aortic tissue of naive and LPS-treated rats, TLR4–/– and respec-
tive wild-type strain C57BL/10ScN were homogenized in
modified RIPA buffer (Tris HCl 50 mM, pH 7.4, tritonX-100
1%, sodium deoxycholate 0.25%, NaCl 150 mM, EDTA
1 mM, PMSF 1 mM, aprotinin 10 mg·mL-1, leupeptin 20 mM,
NaF 50 mM) using a polytron homogenizer (two cycles of
10 s at maximum speed). After centrifugation of homoge-
nates at 9193¥ g for 15 min, protein concentration was deter-
mined by the Bradford assay using BSA as standard
(Bio-Rad Laboratories, Milan, Italy); 30 mg of the denatured
proteins or 40 mg of supernatants obtained from immunopre-
cipitates were separated on 10% or 8% SDS-PAGE and trans-
ferred to a PVDF membrane. Membranes were blocked in
PBS-Tween 20 (0.1%, v v-1) containing 5% non-fat dry milk
for 1 h at room temperature, and then incubated with anti–
PAR2 (1:500) or anti-TLR4 (1:1000) overnight at 4°C. The
filters were washed with PBS-Tween 20 extensively for
30 min, before incubation, for 2 h at 4°C, with the secondary
antibody (1:5000) conjugated with HRP antimouse IgG or
antirabbit IgG, respectively. The membranes were then
washed and immunoreactive bands were visualized using an
Enhanced Chemiluminescence Substrate (Amersham Phar-
macia Biotech, San Diego, CA, USA).
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TLR4 immunoprecipitation and
PAR2 immunoblotting
All steps were performed at 4°C. Aortas, prepared from LPS-
treated or saline-treated rats were washed with Krebs solution
and homogenized in modified RIPA buffer (50 mM Tris-HCI
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.25%
sodium deoxycholate, 1 mM PMSF; 10 mg·mL-1 aprotinin,
20 mM leupeptin, 50 mM NaF). After 30 min, homogenates
were centrifuged for 10 min at 10789¥ g in an eppendorf
microfuge in order to remove nuclei and cell debris, and
300 mL of the resulting supernatant (containing 400 mg of
cleared lysate) were incubated overnight with the rabbit poly-
clonal anti-TLR4 antibody [TLR4 (M300) sc-30002, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA] or normal
rabbit serum (to evaluate non-specific binding) on a rotating
wheel. The antigen–antibody complexes were incubated for
2 h on a rotating wheel with protein A/G – plus Agarose
(sc-2003, Santa Cruz Biotechnology, Inc.). After centrifuga-
tion at 23¥ g for 15 s, the supernatants were collected, trans-
ferred into eppendorfs and conserved at -80°C for Western
blot analysis. The bound complexes were washed once with
lysis buffer, twice with buffer A (10 mM Tris-HCI pH 7.4,
150 mM NaCl, 2 mM EDTA, 0.2% Nonidet P40), twice with
buffer B (10 mM Tris-HCI pH 7.4, 500 mM NaCl, 2 mM EDTA,
0.2% Nonidet P40), and once with 10 mM Tris-HCI pH 7.4.
The supernatants of the beads were collected and immuno-
precipitated material was eluted from the beads by boiling in
Laemmli sample buffer and subjected to SDS-PAGE (8%). The
blot was performed by transferring proteins from a gel to
PVDF membrane at 250 mA for 40 min at room temperature.
The filter was then blocked with 1¥ PBS, 5% non-fat dried
milk for 1 h at room temperature and probed with mono-
clonal antibody anti–PAR2 [1:500, PAR2 (SAM11) sc-13504,
Santa Cruz, Inc.] dissolved in 1¥ PBS, 5% non-fat dried milk at
4°C, overnight. The secondary antibody (anti-mouse IgG HRP
conjugate 1:5000 dilution) was incubated for 2 h at 4°C.
Subsequently, the blot was extensively washed with PBS,
developed using enhanced chemiluminescence detection rea-
gents (Amersham Pharmacia Biotech, Piscataway, NJ, USA)
according to the manufacturer’s instructions, and exposed to
Kodak X-Omat film (Eastman Kodak Co., Rochester, NY,
USA). A protein band of about 40 kDa on X-ray film was
obtained.
Statistical analysis
Data are expressed as mean  SEM. Statistical analysis was
determined by using one or two way ANOVA followed by
Dunnett’s or Bonferroni’s test for multiple comparisons,
respectively, using GraphPad Prism software (GraphPad Soft-
ware Inc., San Diego, CA, USA). Differences were considered
statistically significant when P was less than 0.05.
Results
PAR2AP–induced vasorelaxation is increased
in aortic rings from LPS-treated rats
As already previously shown (Cicala et al., 1999), Western
blot analysis revealed an enhanced expression of the PAR2
receptor following LPS injection when compared with vehicle
at all times tested (Supporting Information Figure S1A).
PAR2AP–induced vasorelaxation was increased in a time-
dependent manner in rat aortic rings harvested 4 and 8 h
following LPS administration (Supporting Information
Figure S1B). Conversely, TLR4 expression was not modified
after LPS treatments, at all times tested (Supporting Informa-
tion Figure S1C).
TLR4 inhibitors, CRC and RSV, reduced
PAR2AP–induced relaxation in naive and
LPS-treated rats
In order to investigate any cross-talk between PAR2 and TLR4
signalling, aortic rings were treated with two different
compounds recently identified as inhibitors of the TLR4
pathway, CRC and RSV. CRC inhibits both ligand-induced
(MyD88-dependent pathway) and ligand-independent
(MyD88-independent, TIR-domain-containing adapter-
inducing interferon-b (TRIF)-dependent pathway) dimeriza-
tion of TLR4 (Youn et al., 2006; Son et al., 2008; Lubbad
et al., 2009), while RSV inhibits specifically the MyD88-
independent, TRIF-dependent pathway (Youn et al., 2005;
Son et al., 2008; Lubbad et al., 2009). In order to verify the
specificity of CRC and RSV, the maximal concentrations of
either CRC (30 mM) or RSV (10 mM) were tested on ACh-
induced vasodilatation. As shown in Figure 1, neither com-
pound affected ACh –induced vasodilatation.
Both CRC (3, 10, 30 mM) and RSV (1, 3, 10 mM) signifi-
cantly and in a concentration-dependent manner reduced
PAR2AP–induced vasorelaxation in naïve rats (Figures 2A,
3A). Similarly, in LPS-treated rats, both CRC (Figure 2B and
C) and RSV (Figure 3B and C) also significantly inhibited
PAR2AP–induced vasorelaxation at the different time points
tested. The inhibitory effects of CRC and RSV on PAR2AP-
induced vasorelaxation were not significantly different
between aortic rings from naïve and endotoxaemic rats.
Moreover, to exclude the possibility that the effect of CRC
and RSV on PAR2AP–induced vasorelaxation was caused by
their antioxidant properties, we pre-treated aortic rings
with SOD (300 U·mL-1) at a concentration known to act as
superoxide anion scavenger. SOD did not modify the
PAR2AP–induced vasorelaxation (EC50 = 3.98 ¥ 10-6 M and
3.80 ¥ 10-6 M in the presence of vehicle and SOD, respec-
tively, data not shown). Finally, to further confirm the
specificity of CRC and RSV on TLR4 signalling, both
inhibitors were tested on aortic rings harvested from
TLR4–/– mice. As shown in Figure 4C, both inhibitors
failed to inhibit PAR2AP–induced vasodilatation, while they
still significantly inhibited the vasodilatation in vessels
obtained from C57BL/10ScN mice (Supporting Information
Figure S3C).
CRC and RSV reduced
PAR2AP–induced hypotension
In order to prove that hypotension induced by selective
activation of the PAR2 receptor involves TLR4 signalling,
CRC (100 mg·kg-1) and RSV (30 mg·kg-1) were administered
before i.v. administration of PAR2AP. Both CRC and RSV
inhibited PAR2AP-induced hypotension in vivo in naïve rats
(Figure 5).
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Physical interaction between PAR2 and TLR4
in naive and LPS-treated rats
To gain further insights into the molecular mechanism of
PAR2/TLR4 cross-talk an immunoprecipitation study was
carried up. In homogenates of aortas obtained from both
naïve and LPS-treated rats, immunoprecipitation of TLR4
receptor followed by PAR2 immunoblot was performed.
Immunoblotting of anti-TLR4 immunoprecipitates with anti-
PAR2 revealed that PAR2 was associated with the TLR4 recep-
tor, as a 40-kDa band consistent with PAR2 core protein
(Gruber et al., 2004) was obtained (Figure 6B lane B). The
complex between the PAR2 and TLR4 receptor was also
evident after in vitro stimulation of aortas with PAR2AP
(Figure 6B lane D). These results suggest that PAR2 was asso-
ciated with TLR4 before, as well as, after receptor activation.
Similar findings have also been obtained in aortas obtained
from endotoxaemic animals (Figure 6B lane E–H). To evaluate
the specificity of the 40-kDa band, cell lysates of aortas stimu-
lated or not with PAR2AP from control and endotoxaemic rats
were incubated with the corresponding normal rabbit serum
instead of anti-TLR-4 antibody (Figure 6B lanes A, C, E, and
G). Western blot analysis performed on the supernatants
obtained from anti-TLR4 immunoprecitates revealed the
presence of PAR2 receptors exclusively in aortas harvested
from LPS-treated rats (Figure 6C).
PAR2 expression is reduced in TLR4–/– mice
In order to confirm the cooperation between PAR2 and TLR4
receptors, we performed a functional study on TLR4–/– mice.
In isolated aortic rings from these mice both ACh-induced
vasodilatation and the endothelium-independent dilator
agent SNP (sodium nitroprusside), induced a similar sized
response in TLR4–/– and wild-type mice (Figure 4A and B).
RT-PCR analysis revealed a significant reduction in PAR2
expression in aortas of TLR4–/– mice compared with those
from wild-type mice (Figure 7A). This finding was confirmed
in the functional study where, PAR2AP–induced vasorelaxa-
tion was significantly reduced in aortic rings harvested from
TLR4–/– mice compared with wild-type mice (Figure 7C).
Western blot analysis for PAR2 did not reveal any significant
difference between TLR4–/– and wild-type mice (Figure 7B).
Discussion
We have previously shown that PAR2 is involved in LPS-
induced hypotension; however, we did not elucidate the
mechanism underlying this involvement of PAR2 in septic
shock (Cicala et al., 1999). At the time, it was not known that
the action of LPS mainly produced through an effect on the
TLR4 receptor. Following recent evidence suggesting a possi-
ble connection between PARs and TLR signalling (Moretti
et al., 2008; Rallabhandi et al., 2008; Uehara et al., 2008), here
we sought to investigate any possible cross-talk between the
PAR2 and TLR4 in vascular tissues. To pursue this, we used two
different approaches: the first ex vivo, pharmacological modu-
lation of isolated aortic rings obtained from naïve and endo-
toxaemic rats. The second in vivo, using PAR2AP-induced
hypotension in anaesthetized rats in order to validate the
data obtained ex vivo. The rationale for using aorta from
LPS-treated rats relies on the finding that LPS injection
induces an increase in PAR2 expression in vascular tissue.
Firstly, we evaluated whether RSV and CRC, two recently
recognized TLR4 antagonists (Youn et al., 2006; Son et al.,
2008; Lubbad et al., 2009), could reduce PAR2AP–induced
vasorelaxation. In aortas from both control and LPS-treated
rats, both of these antagonists significantly inhibited the
PAR2AP–induced vasodilatation without affecting NO release.
The specificity of these effects of CRC and RSV on TLR4
receptor were confirmed by using aortic rings from TLR4–/–
mice; the two antagonists had no effect on PAR2AP-induced
vasodilatation in aortic rings obtained from TLR4–/–, while
both retained their inhibitory activity on aortas obtained
from C57BL/10ScN mice. The finding that the TLR4 antago-
nists had similar effects in aortic rings from either control or
LPS-treated rats suggests that a constitutive functional inter-
action may exist between PAR2 and TLR4. This latter result
together with the finding that PAR2, but not TLR4, expression
is increased in aortic tissue obtained from rats 4 and 8 h after
they had been injected with LPS, indicate that the PAR2 over-
expressed following LPS treatment is not physically associ-
ated with TLR4. This LPS-induced increase in the expression
of the PAR2, measured by quantitative RT-PCR, was also
observed in the aortas and kidneys harvested from TLR4–/–
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Figure 1
Pre-incubation of aortic rings with CRC and RSV did not affect ACh-induced vasodilatation. For each set of experiments, n = 4 rats.
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Figure 2
(A) PAR2AP–induced vasorelaxation was significantly and
concentration-dependently inhibited by CRC in aortic rings har-
vested from control rats (*** P < 0.001 versus vehicle; two-way
ANOVA). CRC (10 mM) pretreatment also inhibited PAR2AP-induced
vasorelaxation in aortic rings harvested from LPS-treated rats at
(B) 4 h (*** = P < 0.001 vs. vehicle) and (C) 8 h (*** = P < 0.001 vs.
vehicle; for each set of experiments, n = 5 rats.
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Figure 3
(A) PAR2AP-induced vasorelaxation was significantly and
concentration-dependently inhibited by RSV in aortic rings harvested
from control rats (*** = P < 0.001 vs. vehicle; two-way ANOVA). RSV
(10 mM) pretreatment also inhibited PAR2AP vasorelaxation in aortic
rings harvested from LPS-treated rats at (B) 4 h (*** = P < 0.001 vs.
vehicle) and (C) 8 h (*** = P < 0.001 vs. vehicle; for each set of
experiments n = 5 rats).
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mice (Supporting Information Figure S2) confirming that
LPS-induced PAR2 overexpression is independent of TLR4
expression not only in the vasculature but also in other
tissues. Hence, the results of this immunoprecipitation study
suggest that PAR2 can interact with TLR4 in normal condi-
tions and that LPS treatment does not increase this interac-
tion. These data are in line with our hypothesis that the
PAR2/TLR4 association is constitutive in vascular tissue and
LPS-induced PAR2 overexpression does not involve a further
increase in the interaction of PAR2 with TLR4. However, as
shown in Supporting Information Figure S3, the PAR2 mono-
clonal antibody SAM11 appears to cross-react with an
unknown target in proteins isolated from PAR2 knockout
mice, as also shown by others (Kagota et al., 2011). In addi-
tion, the same applies to the polyclonal TLR4 antibody [TLR4
(M300) sc-30002] used in this study. Therefore the antibody
reagents available are not yet reliable enough to clearly estab-
lish this interaction in intact tissues.
In order to test whether the above findings are also rel-
evant in vivo, we treated naïve rats with RSV or CRC and then
induced hypotension by a bolus injection of PAR2AP. CRC
and RSV significantly reduced PAR2AP–induced hypotension;
the dose of these antagonist used is known to specifically
inhibit TLR4, as opposed to higher doses (Bengmark, 2006;
Silan, 2008). These data suggest that TLR4 signalling is
involved in PAR2 activation. The fact that RSV, the MyD88-
independent TRIF-dependent pathway inhibitor, was a more
potent inhibitor than CRC in both the ex vivo and in vivo
experiments suggests that PAR2 activation might involve this
specific TLR4 signalling pathway. This mechanism has previ-
ously been proposed by Rallabhandi and colleagues, from
results obtained using transiently PAR2 transfected HEK293T
cells (Rallabhandi et al., 2008). Thus, our data obtained in vivo
confirm the results obtained from our ex vivo experiments, all
indicating that PAR2/TLR4 cross-talk is involved in the modu-
lation of the vascular tone in physiological conditions. When
a pathological stimulus occurs, such as LPS injection, there is
an overexpression of PAR2 that is no longer associated with
TLR4.
The experiments carried out in TLR4–/– mice provide a
proof of concept of this cross-talk between PAR2 and TLR4.
RT-PCR analysis showed that the aortas obtained from TLR4–/–
mice had a reduced expression of PAR2. Similarly, the func-
tional study revealed a significant reduction in PAR2AP–
induced vasodilatation in aortic rings from TLR4–/– mice
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ACh-induced vasodilatation (10 nM–30 mM) (A), as well as SNP-
induced vasodilatation (1 nM–3 mM) (B), were not significantly dif-
ferent in isolated aortic rings harvested from TLR4–/– mice compared
with wild-type littermates, (C) incubation with CRC or RSV did not
affect PAR2AP-induced vasodilatation in aortic rings harvested from
TLR4–/– mice. n = 6 for each group of animals.
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Figure 5
PAR2AP-induced hypotension (0.3 mg·kg-1 i.v.) was significantly
reduced in control rats treated either with (A) CRC or (B) RSV (*P <
0.05; one way ANOVA, n = 4 for each treatment). Values were
expressed as area under the curve (mm2).
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compared to wild-type mice. In order to assess the vascular
reactivity of TLR4–/– mice, we checked both endothelium-
dependent (with ACh) and endothelium-independent (with
SNP) vasodilatation and showed that this was not signifi-
cantly different from that of wild-type mice. These data indi-
cate that, in the absence of TLR4, PAR2 signalling is impaired
most likely because of the lack of cooperation between PAR2
and TLR4.
Conclusions
Our study demonstrates that in vascular tissues, PAR2 and
TLR4 cooperate in terms of molecular signalling both in
physiological and pathological conditions. LPS priming
causes an overexpression of PAR2, which exceeds the TLR4
binding capacity. This finding sheds new light on the dual
role of PAR2 in physiological versus pathological conditions.
Indeed, we hypothesize that when the amount of PAR2
expressed exceeds TLR4 binding capacity, PAR2 could elicit a
detrimental effect. Conversely, when all the PAR2 expressed
are bound to TLR4 it would have a beneficial physiological
effect. Our findings could explain why in some cases activa-
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(A) Physical association of PAR2 with TLR4. Anti PAR2 immunoblot of
antiTLR4 (lanes B, D, F and H) and normal rabbit serum control (lanes
A, C, E and G) immunoprecipitation from lysates of aortas incubated
in the absence (lanes A, B, E and F) and presence of PAR2AP (lanes C,
D, G and H) in naïve (lanes A, B, C, D) and endotoxaemic (lanes E,
F, G, H) rats (n = 3 experiments). (B) Western blot analysis for PAR2
receptor performed on supernatants of TLR4 immunoprecipitates
showed the presence of PAR2 exclusively in aortas harvested from
LPS-treated rats (n = 3 experiments).
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Figure 7
(A) RT-PCR analysis performed on aortas harvested from TLR4–/– and
wild-type mice showed a reduction of PAR2 expression in TLR4–/–
mice (* P < 0.05, n = 3 experiments). (B) Western blot analysis of PAR2
performed on lysates of aortas harvested from TLR4–/– and wild-type
mice revealed no significant differences between the strains (n = 3
experiments). (C) PAR2AP-induced vasorelaxation was significantly
impaired in aortic rings harvested from TLR4–/– mice (***P < 0.001,
n = 7 for each strain).
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tion of PAR2 has been found to induce anti-inflammatory
effects (Fiorucci et al., 2001; Morello et al., 2005; Roviezzo
et al., 2005), whereas others have demonstrated that it results
in pro-inflammatory effects (Fiorucci et al., 2001; Ferrell et al.,
2003; Hyun et al., 2008), and they also help to unravel the
complex role played by this protease-activated receptor in
cardiovascular homeostasis.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 (A) Western blot analysis shows a significant
increase in PAR2 expression in LPS (13.6 U·kg-1) treated rats.
(B) PAR2AP-induced vasodilatation was significantly increased
in aortic rings harvested from LPS-treated rats (4 and 8 h after
LPS) *P < 0.05 versus saline; ***P < 0.001 versus saline; n = 10
for each group. (C) Western blot analysis revealed no differ-
ence in TLR4 expression in LPS-treated compared with naive
rats.
Figure S2 qRT-PCR analysis performed on kidney (A) or on
aorta (B) harvested from TLR4–/– mice demonstrates that LPS
causes an upregulation of PAR2 expression. (*P < 0.05
***P < 0.001; n = 3 experiments).
Figure S3 (A) Western blot analysis showing PAR2 expression
in aorta from wild-type and PAR2 KO mice. (B) Western blot
analysis showing TLR4 expression in aorta from wild-type
and TLR4 KO mice. Blots are representative of 3 different
experiments. (C) CRC (10 mM) and RSV (10 mm) significantly
inhibited PAR2AP-induced vasodilatation in aorta harvested
from C57BL/10ScN mice (*** = P < 0.001 vs. vehicle; n = 3
mice for a total of 10 rings for each group).
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